PRELUDE THERAPEUTICS I

Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

06 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

24 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

09 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

13 Sep 2024 10:00:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

09 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

12 Aug 2024 07:01:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

09 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

03 Jun 2024 07:01:00 By Nasdaq GlobeNewswire

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

09 May 2024 07:01:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

07 May 2024 07:01:00 By Nasdaq GlobeNewswire

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

09 Apr 2024 16:35:00 By Nasdaq GlobeNewswire

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

05 Mar 2024 16:45:00 By Nasdaq GlobeNewswire

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

29 Feb 2024 16:05:08 By Nasdaq GlobeNewswire

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

15 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces $25 Million Private Placement

11 Dec 2023 09:34:10 By Nasdaq GlobeNewswire

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

01 Nov 2023 16:10:00 By Nasdaq GlobeNewswire

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

01 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference 

14 Oct 2023 12:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

29 Aug 2023 08:30:00 By Nasdaq GlobeNewswire

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

03 Aug 2023 08:00:01 By Nasdaq GlobeNewswire